Christian Grohé

机构：DRK Kliniken Berlin, Evangelische Lungenklinik Berlin · ORCID：0000-0003-2724-7647

发表论文 437 篇 · 总被引 19868 次 · h-index 60

代表论文

• Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial (2025 · The Lancet · 被引 91)
• Immune checkpoint inhibitor-associated myocarditis: a novel risk score (2025 · European Heart Journal · 被引 58)
• Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer (2025 · Nature Medicine · 被引 54)
• Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma (2025 · Nature Communications · 被引 14)
• Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. (2025 · Journal of Clinical Oncology · 被引 9)
• First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study (2025 · Lung Cancer · 被引 5)